Literature DB >> 23954027

Exploration of 100 commonly used drugs and supplements on cognition in older adults.

Karen R Obermann1, John C Morris, Catherine M Roe.   

Abstract

BACKGROUND: There are conflicting reports and a lack of evidence-based data regarding effects of medications on cognition in cognitively normal older adults. We explored whether use of 100 common medications taken by older adults is associated with longitudinal cognitive performance.
METHODS: A longitudinal observational cohort was used with analysis of data collected from September 2005 through May 2011 and maintained in the National Alzheimer's Coordinating Center (NACC) Uniform Data Set. Participants were aged 50 years or older and cognitively normal (N = 4414). Composite scores were constructed from 10 psychometric tests. Scores for each participant reflecting change in the psychometric composite score from the baseline clinical assessment to the next assessment were calculated. General linear models were used to test whether the mean composite change score differed for participants who reported starting, stopping, continuing, or not taking each of the 100 most frequently used medications in the NACC sample.
RESULTS: The average time between assessments was 1.2 years (SD = 0.42). Nine medications showed a difference (P < .05) across the four participant groups in mean psychometric change scores from the first to the second assessment. Medications associated with improved psychometric performance were naproxen, calcium-vitamin D, ferrous sulfate, potassium chloride, flax, and sertraline. Medications associated with declining psychometric performance were bupropion, oxybutynin, and furosemide.
CONCLUSIONS: Reported use of common medications is associated with cognitive performance in older adults, but studies are needed to investigate the mechanisms underlying these effects.
Copyright © 2013 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cognition; Medications; National Alzheimer's Coordinating Center; Psychometric tests

Mesh:

Substances:

Year:  2013        PMID: 23954027      PMCID: PMC3823812          DOI: 10.1016/j.jalz.2012.12.002

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  41 in total

1.  The effects of bupropion on cognitive functions in healthy subjects.

Authors:  Martin Siepmann; Kathrin Werner; Christoph Schindler; Reinhard Oertel; Wilhelm Kirch
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

Review 2.  Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly.

Authors:  Richard Scheife; Masayuki Takeda
Journal:  Clin Ther       Date:  2005-02       Impact factor: 3.393

3.  Decreased persistence to cholinesterase inhibitor therapy with concomitant use of drugs that can impair cognition.

Authors:  Stephen J Kogut; Diala El-Maouche; Susan M Abughosh
Journal:  Pharmacotherapy       Date:  2005-12       Impact factor: 4.705

4.  Relation of prescription nonsteroidal antiinflammatory drug use to cognitive function among community-dwelling elderly.

Authors:  J T Hanlon; K E Schmader; L R Landerman; R D Horner; G G Fillenbaum; C F Pieper; W E Wall; M J Koronkowski; H J Cohen
Journal:  Ann Epidemiol       Date:  1997-02       Impact factor: 3.797

Review 5.  Is benzodiazepine use a risk factor for cognitive decline and dementia? A literature review of epidemiological studies.

Authors:  Helene Verdoux; Rajaa Lagnaoui; Bernard Begaud
Journal:  Psychol Med       Date:  2005-03       Impact factor: 7.723

6.  Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study.

Authors:  Marie L Ancelin; Sylvaine Artero; Florence Portet; Anne-Marie Dupuy; Jacques Touchon; Karen Ritchie
Journal:  BMJ       Date:  2006-02-01

7.  Drugs with anticholinergic properties and cognitive performance in the elderly: results from the PAQUID Study.

Authors:  Nathalie Lechevallier-Michel; Mathieu Molimard; Jean-François Dartigues; Colette Fabrigoule; Annie Fourrier-Réglat
Journal:  Br J Clin Pharmacol       Date:  2005-02       Impact factor: 4.335

8.  Diagnosis of hypertension and high blood pressure levels negatively affect cognitive function in older adults.

Authors:  Shari R Waldstein; Jessica R P Brown; Karl J Maier; Leslie I Katzel
Journal:  Ann Behav Med       Date:  2005-06

Review 9.  Anemia in the elderly.

Authors:  Wendy W Pang; Stanley L Schrier
Journal:  Curr Opin Hematol       Date:  2012-05       Impact factor: 3.284

10.  The concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice?

Authors:  Ryan M Carnahan; Brian C Lund; Paul J Perry; Elizabeth A Chrischilles
Journal:  J Am Geriatr Soc       Date:  2004-12       Impact factor: 5.562

View more
  8 in total

Review 1.  Review of the efficacy and safety of fesoterodine for treating overactive bladder and urgency urinary incontinence in elderly patients.

Authors:  Adrian Wagg; Matthias Oelke; Javier C Angulo; David Scholfield; Daniel Arumi
Journal:  Drugs Aging       Date:  2015-02       Impact factor: 3.923

Review 2.  Over-Prescribed Medications, Under-Appreciated Risks: A Review of the Cognitive Effects of Anticholinergic Medications in Older Adults.

Authors:  Daniel M I Britt; Gregory S Day
Journal:  Mo Med       Date:  2016 May-Jun

3.  Amyloid Imaging, Cerebrospinal Fluid Biomarkers Predict Driving Performance Among Cognitively Normal Individuals.

Authors:  Catherine M Roe; Peggy P Barco; Denise M Head; Nupur Ghoshal; Natalie Selsor; Ganesh M Babulal; Rebecca Fierberg; Elizabeth K Vernon; Neal Shulman; Ann Johnson; Scot Fague; Chengjie Xiong; Elizabeth A Grant; Angela Campbell; Brian R Ott; David M Holtzman; Tammie L S Benzinger; Anne M Fagan; David B Carr; John C Morris
Journal:  Alzheimer Dis Assoc Disord       Date:  2017 Jan-Mar       Impact factor: 2.703

4.  Shen-zhi-ling oral liquid improves behavioral and psychological symptoms of dementia in Alzheimer's disease.

Authors:  Weidong Pan; Qiudong Wang; Shin Kwak; Yu Song; Baofeng Qin; Mingzhe Wang; Yoshiharu Yamamoto
Journal:  Evid Based Complement Alternat Med       Date:  2014-05-18       Impact factor: 2.629

5.  Direct and indirect risk associated with the use of dietary supplements among persons with dementia in a Norwegian memory clinic.

Authors:  Hilde Risvoll; Trude Giverhaug; Kjell H Halvorsen; Marit Waaseth; Frauke Musial
Journal:  BMC Complement Altern Med       Date:  2017-05-12       Impact factor: 3.659

6.  Effects of Trazodone on Sleep Quality and Cognitive Function in Arteriosclerotic Cerebral Small Vessel Disease Comorbid With Chronic Insomnia.

Authors:  Jihui Wang; Sanxin Liu; Chongbang Zhao; Hongying Han; Xiaodong Chen; Jiong Tao; Zhengqi Lu
Journal:  Front Psychiatry       Date:  2020-06-30       Impact factor: 4.157

7.  Active Fraction Combination from Liuwei Dihuang Decoction (LW-AFC) Alleviated the LPS-Induced Long-Term Potentiation Impairment and Glial Cells Activation in Hippocampus of Mice by Modulating Immune Responses.

Authors:  Ju Zeng; Bin Cheng; Yan Huang; Xiaorui Zhang; Chen Wang; Na Sun; Gang Liu; Xiaorui Cheng; Yongxiang Zhang; Wenxia Zhou
Journal:  Evid Based Complement Alternat Med       Date:  2019-09-16       Impact factor: 2.629

8.  Preclinical Alzheimer's disease and longitudinal driving decline.

Authors:  Catherine M Roe; Ganesh M Babulal; Denise M Head; Sarah H Stout; Elizabeth K Vernon; Nupur Ghoshal; Brad Garland; Peggy P Barco; Monique M Williams; Ann Johnson; Rebecca Fierberg; M Scot Fague; Chengjie Xiong; Elizabeth Mormino; Elizabeth A Grant; David M Holtzman; Tammie L S Benzinger; Anne M Fagan; Brian R Ott; David B Carr; John C Morris
Journal:  Alzheimers Dement (N Y)       Date:  2017-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.